Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BCYC 
Bicycle Therapeutics Ltd (BCYC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/16/2025: BCYC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $26.27
1 Year Target Price $26.27
| 5 | Strong Buy |
| 5 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.84% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 531.87M USD | Price to earnings Ratio - | 1Y Target Price 26.27 |
Price to earnings Ratio - | 1Y Target Price 26.27 | ||
Volume (30-day avg) 13 | Beta 1.47 | 52 Weeks Range 6.10 - 28.67 | Updated Date 07/16/2025 |
52 Weeks Range 6.10 - 28.67 | Updated Date 07/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -703.66% |
Management Effectiveness
Return on Assets (TTM) -21.69% | Return on Equity (TTM) -37.07% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -225076134 | Price to Sales(TTM) 20.68 |
Enterprise Value -225076134 | Price to Sales(TTM) 20.68 | ||
Enterprise Value to Revenue 21.22 | Enterprise Value to EBITDA -2.14 | Shares Outstanding 47761800 | Shares Floating 1884365 |
Shares Outstanding 47761800 | Shares Floating 1884365 | ||
Percent Insiders 1.46 | Percent Institutions 93.44 |
Upturn AI SWOT
Bicycle Therapeutics Ltd
Company Overview
History and Background
Bicycle Therapeutics Ltd. was founded in 2009 and is headquartered in Cambridge, UK. The company is a biopharmaceutical company pioneering a new class of medicines based on its proprietary bicyclic peptide (Bicycleu00ae) technology.
Core Business Areas
- Oncology: Developing Bicycle Toxin Conjugates (BTCs) and Bicycle Radio Conjugates (BRCs) for the treatment of cancer.
- Other Therapeutic Areas: Exploring the potential of Bicycle technology in other therapeutic areas, including immune-oncology.
Leadership and Structure
Dr. Kevin Lee is the Chief Executive Officer. The company has a Board of Directors composed of experienced individuals from the biotechnology and pharmaceutical industries. The organizational structure is typical of a biotechnology company, with research, development, clinical, and commercial functions.
Top Products and Market Share
Key Offerings
- BT8009: A Bicycle Toxin Conjugate (BTC) targeting Nectin-4, currently in Phase I/II clinical trials for advanced solid tumors. Market share data is not yet available as it is still in development. Competitors include companies developing antibody-drug conjugates (ADCs) targeting Nectin-4, such as Astellas/Seagen with PADCEV.
- BT5500: A Bicycle Toxin Conjugate (BTC) targeting EphA2, currently in Phase I/II clinical trials for advanced solid tumors. Market share data is not yet available as it is still in development. Competitors include companies developing other EphA2 targeting therapies, such as ADCs or small molecule inhibitors.
Market Dynamics
Industry Overview
The biotechnology industry is highly competitive, with numerous companies developing novel therapeutics for various diseases. There is a growing focus on targeted therapies and personalized medicine.
Positioning
Bicycle Therapeutics is positioned as a pioneer in bicyclic peptide technology, offering a unique approach to drug development with potential advantages in terms of target specificity, tumor penetration, and safety.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars annually. Bicycle Therapeutics is targeting specific cancer subtypes, which represent a significant portion of this overall market. The company's future is dependent on the success of its novel drug candidates.
Upturn SWOT Analysis
Strengths
- Proprietary Bicycle technology platform
- Potential for improved target specificity and tumor penetration
- Strong intellectual property position
- Experienced management team
- Promising early-stage clinical data
Weaknesses
- Early-stage clinical development
- High risk of clinical trial failure
- Dependence on partnerships for funding and commercialization
- Limited commercial infrastructure
Opportunities
- Expansion of Bicycle technology platform to new therapeutic areas
- Potential for strategic partnerships and collaborations
- Advancement of clinical programs to later stages
- Potential for breakthrough therapy designations
- Expansion of manufacturing capabilities
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- MRNA
- LLY
- AZN
Competitive Landscape
Bicycle Therapeutics' competitive advantages lie in its proprietary Bicycle technology. Disadvantages include its relatively small size and limited resources compared to larger pharmaceutical companies. This data can change at any given moment.
Growth Trajectory and Initiatives
Historical Growth: Bicycle Therapeutics' historical growth is characterized by its advancement of its Bicycle platform and clinical programs.
Future Projections: Future projections for Bicycle Therapeutics are dependent on the success of its clinical trials and partnerships. Analyst estimates vary, but generally project significant growth potential if clinical milestones are achieved.
Recent Initiatives: Recent initiatives include advancing clinical trials for BT8009 and BT5500, expanding manufacturing capabilities, and exploring new partnerships.
Summary
Bicycle Therapeutics is a biotechnology company developing novel therapeutics based on its Bicycle platform. The company has promising early-stage clinical data and a strong intellectual property position. However, it faces the high risk of clinical trial failure and competition from larger pharmaceutical companies. Success depends on clinical milestones and partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Bicycle Therapeutics Ltd. website
- SEC filings
- Analyst reports
- Industry news sources
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and analyst estimates, which are subject to change. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bicycle Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2019-05-23 | CEO & Executive Director Dr. Kevin Lee M.B.A., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 305 | |
Full time employees 305 | |||
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.